Farde L, Hall H
Department of Psychiatry and Psychology, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden.
Arzneimittelforschung. 1992 Feb;42(2A):260-4.
The imaging technique Positron Emission Tomography (PET) allows examination of chemical neurotransmission in brain. Of key importance for PET-research on neuroreceptors is the development of suitable radiolabelled tracers (ligands). This paper illustrates the multidisciplinary research activities necessary for ligand development. The selective D1- and D2-dopamine receptor antagonists SCH 23390 and raclopride (CAS 84225-95-6), respectively, were labelled with [3H] and characterized in biochemical studies in vitro on human brain homogenates and in autoradiographic studies on cryosections from human hemispheres. The experimental information was used to interpret and support the PET-findings with [11C]-labelled SCH 23390 and raclopride in vivo in humans. In conclusion, these ligands can be used to quantitatively examine dopamine receptors in the human basal ganglia in vivo. An applied study for PET-determination of D1- and D2-dopamine receptor occupancy during antipsychotic drug treatment indicates that the D2-dopamine receptor and possibly also the D1-dopamine receptor are targets for neuroleptic drug action.
成像技术正电子发射断层扫描(PET)可用于检查大脑中的化学神经传递。对于神经受体的PET研究而言,开发合适的放射性标记示踪剂(配体)至关重要。本文阐述了配体开发所需的多学科研究活动。选择性D1和D2多巴胺受体拮抗剂SCH 23390和雷氯必利(CAS 84225-95-6)分别用[3H]标记,并在人脑匀浆的体外生化研究以及人半球冰冻切片的放射自显影研究中进行了表征。这些实验信息被用于解释和支持[11C]标记的SCH 23390和雷氯必利在人体体内的PET研究结果。总之,这些配体可用于在体内定量检测人基底神经节中的多巴胺受体。一项关于PET测定抗精神病药物治疗期间D1和D2多巴胺受体占有率的应用研究表明,D2多巴胺受体以及可能的D1多巴胺受体是抗精神病药物作用的靶点。